|
1
|
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
|
N Engl J Med
|
2005
|
13.01
|
|
2
|
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
|
J Clin Oncol
|
2004
|
12.89
|
|
3
|
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
|
Lancet
|
2008
|
10.74
|
|
4
|
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
|
Nat Med
|
2008
|
10.12
|
|
5
|
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
|
J Clin Oncol
|
2008
|
7.35
|
|
6
|
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
|
Lancet
|
2009
|
5.82
|
|
7
|
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
|
J Clin Oncol
|
2009
|
4.27
|
|
8
|
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
4.19
|
|
9
|
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2008
|
3.97
|
|
10
|
Second-line treatment of advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
3.95
|
|
11
|
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
|
Oncologist
|
2009
|
3.92
|
|
12
|
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.
|
Cancer Res
|
2002
|
3.68
|
|
13
|
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2006
|
3.52
|
|
14
|
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
3.51
|
|
15
|
Non-small-cell lung cancer.
|
Lancet
|
2011
|
3.45
|
|
16
|
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
|
J Clin Oncol
|
2007
|
2.93
|
|
17
|
Prognostic gene signatures for non-small-cell lung cancer.
|
Proc Natl Acad Sci U S A
|
2009
|
2.84
|
|
18
|
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
|
J Clin Oncol
|
2005
|
2.76
|
|
19
|
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
|
N Engl J Med
|
2013
|
2.38
|
|
20
|
K-ras mutations in non-small-cell lung carcinoma: a review.
|
Clin Lung Cancer
|
2006
|
2.29
|
|
21
|
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.
|
J Thorac Oncol
|
2009
|
2.29
|
|
22
|
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
|
J Clin Oncol
|
2008
|
2.20
|
|
23
|
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
|
Clin Lung Cancer
|
2006
|
2.14
|
|
24
|
Three-gene prognostic classifier for early-stage non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
2.10
|
|
25
|
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.
|
J Clin Oncol
|
2003
|
2.09
|
|
26
|
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
|
J Clin Oncol
|
2009
|
2.08
|
|
27
|
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
2.03
|
|
28
|
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
|
Lancet Oncol
|
2013
|
1.99
|
|
29
|
EGFR mutations and lung cancer.
|
Annu Rev Pathol
|
2011
|
1.89
|
|
30
|
Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer.
|
Proc Natl Acad Sci U S A
|
2011
|
1.88
|
|
31
|
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
|
J Clin Oncol
|
2009
|
1.88
|
|
32
|
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.84
|
|
33
|
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
|
J Natl Cancer Inst
|
2010
|
1.83
|
|
34
|
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2006
|
1.80
|
|
35
|
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
|
J Clin Oncol
|
2013
|
1.75
|
|
36
|
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
1.74
|
|
37
|
Molecular predictive and prognostic markers in non-small-cell lung cancer.
|
Lancet Oncol
|
2009
|
1.74
|
|
38
|
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
|
J Clin Oncol
|
2008
|
1.69
|
|
39
|
Influence of sex on toxicity and treatment outcome in small-cell lung cancer.
|
J Clin Oncol
|
2005
|
1.66
|
|
40
|
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
|
Lung Cancer
|
2005
|
1.65
|
|
41
|
Predictors of referral for specialized psychosocial oncology care in patients with metastatic cancer: the contributions of age, distress, and marital status.
|
J Clin Oncol
|
2008
|
1.59
|
|
42
|
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
|
J Clin Oncol
|
2012
|
1.58
|
|
43
|
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
|
J Thorac Cardiovasc Surg
|
2007
|
1.58
|
|
44
|
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
|
J Clin Oncol
|
2007
|
1.57
|
|
45
|
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
|
Lancet Oncol
|
2003
|
1.57
|
|
46
|
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
|
J Clin Oncol
|
2008
|
1.57
|
|
47
|
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
|
Lung Cancer
|
2005
|
1.52
|
|
48
|
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2002
|
1.51
|
|
49
|
The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
|
Clin Cancer Res
|
2010
|
1.51
|
|
50
|
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
|
J Thorac Oncol
|
2013
|
1.50
|
|
51
|
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
|
J Thorac Oncol
|
2010
|
1.49
|
|
52
|
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
|
J Clin Oncol
|
2006
|
1.48
|
|
53
|
Adjuvant chemotherapy for resected non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
1.46
|
|
54
|
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.41
|
|
55
|
The seventh tumor, node, metastasis staging system and lung cancer treatment choices: a matter of would, could, and should.
|
J Thorac Oncol
|
2010
|
1.38
|
|
56
|
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.
|
Clin Cancer Res
|
2003
|
1.38
|
|
57
|
Optimized application of penalized regression methods to diverse genomic data.
|
Bioinformatics
|
2011
|
1.37
|
|
58
|
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
|
J Clin Oncol
|
2008
|
1.35
|
|
59
|
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.35
|
|
60
|
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
|
Lung Cancer
|
2004
|
1.32
|
|
61
|
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
|
J Thorac Oncol
|
2012
|
1.31
|
|
62
|
Understanding prognostic gene expression signatures in lung cancer.
|
Clin Lung Cancer
|
2009
|
1.30
|
|
63
|
Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
|
J Clin Oncol
|
2010
|
1.27
|
|
64
|
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
|
Clin Cancer Res
|
2007
|
1.26
|
|
65
|
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
|
Cancer
|
2002
|
1.25
|
|
66
|
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.25
|
|
67
|
Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
|
J Thorac Oncol
|
2006
|
1.24
|
|
68
|
Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
|
Lung Cancer
|
2009
|
1.24
|
|
69
|
L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.
|
Clin Cancer Res
|
2012
|
1.24
|
|
70
|
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
|
J Thorac Oncol
|
2007
|
1.20
|
|
71
|
Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers.
|
J Thorac Oncol
|
2011
|
1.17
|
|
72
|
Prevention and management of bone metastases in lung cancer: a review.
|
J Thorac Oncol
|
2009
|
1.16
|
|
73
|
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
|
J Thorac Oncol
|
2010
|
1.16
|
|
74
|
Novel candidate tumor marker genes for lung adenocarcinoma.
|
Oncogene
|
2002
|
1.15
|
|
75
|
Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.
|
Clin Cancer Res
|
2004
|
1.15
|
|
76
|
Does intensive follow-up alter outcome in patients with advanced lung cancer?
|
J Thorac Oncol
|
2007
|
1.14
|
|
77
|
Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
|
J Thorac Oncol
|
2014
|
1.13
|
|
78
|
The IASLC Lung Cancer Staging Project: data elements for the prospective project.
|
J Thorac Oncol
|
2009
|
1.13
|
|
79
|
Targeting angiogenesis in the treatment of lung cancer.
|
J Thorac Oncol
|
2008
|
1.10
|
|
80
|
Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors.
|
BMC Cancer
|
2010
|
1.09
|
|
81
|
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
|
Pharmacogenet Genomics
|
2009
|
1.09
|
|
82
|
Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
|
Clin Lung Cancer
|
2011
|
1.09
|
|
83
|
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.08
|
|
84
|
Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.
|
J Thorac Oncol
|
2008
|
1.07
|
|
85
|
The desire for hastened death in patients with metastatic cancer.
|
J Pain Symptom Manage
|
2007
|
1.07
|
|
86
|
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
1.07
|
|
87
|
KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer.
|
Clin Cancer Res
|
2007
|
1.07
|
|
88
|
KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
|
J Thorac Oncol
|
2013
|
1.05
|
|
89
|
Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer.
|
J Clin Oncol
|
2010
|
1.05
|
|
90
|
Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study.
|
J Clin Oncol
|
2010
|
1.04
|
|
91
|
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
|
Eur J Cancer
|
2008
|
1.04
|
|
92
|
Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
|
J Clin Oncol
|
2010
|
1.03
|
|
93
|
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
|
Clin Cancer Res
|
2010
|
1.03
|
|
94
|
Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma.
|
J Thorac Oncol
|
2013
|
1.02
|
|
95
|
Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada.
|
J Clin Oncol
|
2012
|
1.01
|
|
96
|
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
|
Chest
|
2005
|
1.01
|
|
97
|
Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma.
|
Radiother Oncol
|
2012
|
1.00
|
|
98
|
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
|
Clin Lung Cancer
|
2006
|
0.99
|
|
99
|
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
|
J Clin Oncol
|
2005
|
0.99
|
|
100
|
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
|
Lung Cancer
|
2012
|
0.99
|
|
101
|
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.99
|
|
102
|
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.98
|
|
103
|
Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
|
Curr Opin Oncol
|
2008
|
0.98
|
|
104
|
The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer.
|
Psychooncology
|
2007
|
0.98
|
|
105
|
Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience.
|
Lung Cancer
|
2009
|
0.98
|
|
106
|
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.97
|
|
107
|
Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence.
|
Chest
|
2005
|
0.96
|
|
108
|
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
|
J Clin Oncol
|
2011
|
0.96
|
|
109
|
Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
|
J Clin Oncol
|
2005
|
0.96
|
|
110
|
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
|
J Clin Oncol
|
2009
|
0.96
|
|
111
|
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
|
Cochrane Database Syst Rev
|
2015
|
0.96
|
|
112
|
Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
|
J Thorac Oncol
|
2012
|
0.94
|
|
113
|
Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study.
|
Cancer
|
2012
|
0.94
|
|
114
|
Small cell lung cancer and targeted therapies.
|
Curr Opin Oncol
|
2007
|
0.94
|
|
115
|
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
|
J Thorac Oncol
|
2008
|
0.94
|
|
116
|
Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.
|
Lung Cancer
|
2003
|
0.93
|
|
117
|
Immunotherapy for lung cancer.
|
J Thorac Oncol
|
2008
|
0.92
|
|
118
|
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
|
J Thorac Oncol
|
2006
|
0.92
|
|
119
|
Surgery for limited stage small cell lung cancer: time to fish or cut bait.
|
J Thorac Oncol
|
2010
|
0.91
|
|
120
|
Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures.
|
J Proteome Res
|
2010
|
0.91
|
|
121
|
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
|
J Clin Oncol
|
2007
|
0.91
|
|
122
|
Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.
|
Horm Cancer
|
2012
|
0.90
|
|
123
|
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.89
|
|
124
|
Pharmacogenetic and germline prognostic markers of lung cancer.
|
J Thorac Oncol
|
2011
|
0.89
|
|
125
|
Molecular selection trumps clinical selection.
|
J Clin Oncol
|
2011
|
0.89
|
|
126
|
Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review.
|
Crit Rev Oncol Hematol
|
2006
|
0.88
|
|
127
|
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
|
Lung Cancer
|
2005
|
0.88
|
|
128
|
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.
|
Ther Adv Med Oncol
|
2011
|
0.87
|
|
129
|
Erlotinib in the treatment of non-small cell lung cancer.
|
Expert Rev Anticancer Ther
|
2005
|
0.86
|
|
130
|
Prognostic gene expression signature for squamous cell carcinoma of lung.
|
Clin Cancer Res
|
2010
|
0.86
|
|
131
|
Should aggressive surgery ever be part of the management of small cell lung cancer?
|
Thorac Surg Clin
|
2004
|
0.86
|
|
132
|
Chemotherapy and surgery for operable NSCLC.
|
Lancet
|
2007
|
0.86
|
|
133
|
Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.86
|
|
134
|
Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
|
Hematol Oncol Clin North Am
|
2004
|
0.86
|
|
135
|
Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study.
|
Lung Cancer
|
2004
|
0.86
|
|
136
|
Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.
|
J Thorac Cardiovasc Surg
|
2009
|
0.85
|
|
137
|
A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.85
|
|
138
|
Second-hand smoke as a predictor of smoking cessation among lung cancer survivors.
|
J Clin Oncol
|
2014
|
0.85
|
|
139
|
A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.84
|
|
140
|
Maintenance therapy in advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2010
|
0.84
|
|
141
|
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma.
|
Cancer
|
2010
|
0.83
|
|
142
|
Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.
|
J Thorac Oncol
|
2010
|
0.83
|
|
143
|
Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
144
|
Adjuvant chemotherapy after pulmonary resection for lung cancer.
|
Thorac Surg Clin
|
2013
|
0.83
|
|
145
|
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
|
Clin Lung Cancer
|
2011
|
0.82
|
|
146
|
Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.
|
J Clin Oncol
|
2008
|
0.82
|
|
147
|
Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer.
|
J Thorac Oncol
|
2012
|
0.82
|
|
148
|
Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?
|
Treat Respir Med
|
2005
|
0.82
|
|
149
|
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.
|
J Thorac Oncol
|
2014
|
0.81
|
|
150
|
Treatment of small-cell lung cancer in elderly patients.
|
Cancer
|
2010
|
0.81
|
|
151
|
Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
|
J Natl Cancer Inst
|
2010
|
0.81
|
|
152
|
Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
|
Cancer
|
2009
|
0.81
|
|
153
|
Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
|
J Thorac Oncol
|
2012
|
0.81
|
|
154
|
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
|
J Thorac Oncol
|
2015
|
0.81
|
|
155
|
Lung cancer screening with low-dose computed tomography: Canadian experience.
|
Can Assoc Radiol J
|
2007
|
0.80
|
|
156
|
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
|
Lung Cancer
|
2013
|
0.80
|
|
157
|
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
|
J Thorac Oncol
|
2009
|
0.80
|
|
158
|
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.80
|
|
159
|
The communal coping model and cancer pain: the roles of catastrophizing and attachment style.
|
J Pain
|
2012
|
0.80
|
|
160
|
Treatment of recurrent small cell lung cancer.
|
Hematol Oncol Clin North Am
|
2004
|
0.80
|
|
161
|
The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
|
J Thorac Oncol
|
2010
|
0.79
|
|
162
|
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
|
Cancer Med
|
2014
|
0.79
|
|
163
|
Second line chemotherapy for NSCLC: establishing a gold standard.
|
Lung Cancer
|
2002
|
0.79
|
|
164
|
Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine.
|
J Thorac Oncol
|
2013
|
0.79
|
|
165
|
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
|
Eur J Cancer
|
2013
|
0.78
|
|
166
|
Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group.
|
J Thorac Oncol
|
2009
|
0.78
|
|
167
|
NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
|
J Thorac Oncol
|
2014
|
0.77
|
|
168
|
Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor.
|
J Thorac Oncol
|
2015
|
0.77
|
|
169
|
Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.
|
Clin Lung Cancer
|
2013
|
0.77
|
|
170
|
Ongoing and future trials of biologic therapies in lung cancer.
|
Lung Cancer
|
2003
|
0.77
|
|
171
|
Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
|
J Natl Cancer Inst
|
2007
|
0.77
|
|
172
|
Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
|
Lung Cancer
|
2013
|
0.77
|
|
173
|
Postoperative chemotherapy in nonsmall cell lung cancer: a systematic review.
|
Ann Thorac Surg
|
2006
|
0.77
|
|
174
|
A targeted approach to reducing lung cancer mortality.
|
J Clin Oncol
|
2005
|
0.77
|
|
175
|
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
|
J Thorac Oncol
|
2008
|
0.76
|
|
176
|
Surgical treatment of small cell lung cancer.
|
Semin Oncol
|
2003
|
0.75
|
|
177
|
Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
|
Lung Cancer
|
2002
|
0.75
|
|
178
|
Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib.
|
J Thorac Oncol
|
2015
|
0.75
|
|
179
|
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.
|
J Thorac Oncol
|
2015
|
0.75
|
|
180
|
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
0.75
|
|
181
|
Resident preparedness in discussing prognosis in patients with advanced lung cancer.
|
Support Care Cancer
|
2009
|
0.75
|
|
182
|
A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
|
Biotechnol Annu Rev
|
2005
|
0.75
|
|
183
|
Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine.
|
J Thorac Cardiovasc Surg
|
2008
|
0.75
|
|
184
|
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
|
Clin Lung Cancer
|
2003
|
0.75
|